With this study, we hope to promote the application of neoadjuvant therapy of ensartinib for ALK-positive patients with advanced NSCLC and to promote the study of the characterization of the immune microenvironment of NSCLC patients after treatment with ALK inhibitors. The gene discussed is ALK; the disease is non-small cell lung carcinoma.